AI in Bioinformatics Market Report Scope & Overview:

The AI in bioinformatics market was valued at USD 2.34 billion in 2025 and is expected to reach USD 11.37 billion by 2035, growing at a CAGR of 17.36% from 2026–2035.

The AI in bioinformatics market experiences a healthy growth rate across the globe on account of the increasing need for sophisticated data analysis in genomics, proteomics, and drug discovery, and the increased usage of AI-enabled platforms in pharmaceuticals, biotech, and healthcare. Additionally, there is growing use of precision medicine efforts, multi-omics research, and clinical genomics applications, along with the growing adoption of cloud-based bioinformatics solutions and generative AI technologies.

AWS and Palantir have enhanced their capabilities of providing AI solutions for bioinformatics by introducing innovative platforms that facilitate genomics, drug discovery, and clinical trial processes. For instance, AWS has added new capabilities to its HealthOmics platform, such as workflows integrated with VPC, IDE integration, and the new Amazon Bio Discovery application, whereas Palantir has introduced enhanced Life Sciences capabilities with AI-enabled clinical trials automation, generative AI data mapping, and major collaborations in health research.

Market Size and Forecast

• Market Size 2026E: USD 2.69 Billion

• Market Size 2035: USD 11.37 Billion

• CAGR (2026 - 2035): 17.36%

• Fastest Growing Region: Asia Pacific

• Largest Region: North America 

To Get more information On AI in Bioinformatics Market - Request Free Sample Report

AI in Bioinformatics Market Trends

• Cloud-based bioinformatics tools are increasingly favored, providing scalable collaboration capabilities among global research collaborations.

• Foundation models are revolutionizing protein folding and design, cutting down time to develop drugs.

• Growing requirements for precision medicine have led to double-digit CAGR for genomics and clinical bioinformatics.

• Merging genomics, proteomics, and metabolomics with artificial intelligence is revealing new biological knowledge for diseases.

• The involvement of genomic information in sensitive cases makes secure AI platforms essential, especially when HIPAA/GDPR are involved.

The US AI in Bioinformatics Market Size Outlook

The U.S. AI in bioinformatics market was valued at USD 0.93 billion in 2025 and is expected to reach around USD 4.36 billion by 2035, growing at a CAGR of 18.78% from 2026–2035.

The US artificial intelligence in bioinformatics market is regarded among the most technologically mature globally due to the presence of key pharmaceutical and biotech companies, top-tier academic research institutes, and healthcare organizations, along with growing penetration of AI-enabled platforms used in genomics, proteomics, drug discovery, and precision medicine. Top companies like Amazon AWS, Palantir Technologies, IBM, NVIDIA, Microsoft, Thermo Fisher Scientific, and Illumina are increasingly investing in their AI-based bioinformatics product suites, which feature improved scalability, cutting-edge machine learning, generative AI, and cloud solutions to enable biomedical and clinical applications.

Government support through the US National AI Research Resource, NIH-sponsored genomics programs, and government funding in precision medicine is accelerating the use of AI-enabled bioinformatics products and services in the US market. Favorable government policies related to healthcare innovation, cloud data infrastructure, and biomedical research are contributing significantly towards investment in genomics, proteomics, and drug discovery solutions.

AI in Bioinformatics Market Segment Analysis

• By Component, software dominated the AI in bioinformatics market with 35.78% share in 2025, services are also fastest growing CAGR segment.

• By Deployment, Cloud-based dominated the AI in bioinformatics market with 51.23% share in 2025, while it is also fastest growing CAGR segment.

• By Technology, machine learning & deep learning dominated the AI in bioinformatics market with 41.38% share in 2025, while generative ai / foundation models fastest growing CAGR segment.

• By Application, genomics & sequence analysis dominated the AI in bioinformatics market with 35.12% share in 2025, while clinical genomics & precision medicine is fastest growing CAGR segment.

• By End User, pharmaceutical & biotechnology companies segment dominated the AI in Bioinformatics market with 42.35% share in 2025, while hospitals & diagnostic laboratories fastest growing CAGR segment.

By Component, software segment dominates the AI in bioinformatics market and services represents the fastest-growing segment

The software segment accounted for the majority share of the AI in bioinformatics market in 2025 owing to the pivotal importance of software in genomic sequencing, drug discovery using AI, and bioinformatics workflow automation. The extensive acceptance of software solutions by pharma organizations, R&D institutes, and clinical labs has made it the most valuable offering within the market.

The services segment is emerging as the fastest-growing area in the AI in Bioinformatics market, fuelled by rising demand for outsourced expertise, scalable AI integration, and end-to-end bioinformatics support. Service providers are increasingly offering cloud-based analytics, machine learning-driven insights, and generative AI capabilities to accelerate drug discovery, clinical genomics, and precision medicine adoption.

By Deployment, cloud-based dominates the AI in bioinformatics market and also represents the fastest-growing segment

Cloud Deployment emerged as the dominant segment in the market for AI in Bioinformatics in 2025 because of the rising dependence on scalable IT infrastructure, processing of large amounts of data, and collaboration among researchers. Due to the increasingly complex nature of the genomics data and other multi-omics data, there is an increased demand for cloud-enabled platforms in bioinformatics.

Cloud-based systems are also expanding at the fastest pace, supported by rapid digital transformation in life sciences, increasing AI workload requirements, and the shift toward remote, integrated research ecosystems. The growing emphasis on secure data sharing across global research networks is further accelerating cloud adoption, as compliance with HIPAA/GDPR.

By Technology, Machine Learning & Deep Learning dominates the AI in bioinformatics market, while generative AI and foundation models is the fastest-growing segment

Machine Learning & Deep Learning led the way in terms of market share in the AI in bioinformatics industry in 2025 owing to the high level of effectiveness in processing complex biological data and making precise predictions in genomics, proteomics, and drug discovery. The applications of Machine Learning & Deep Learning are diverse from pattern recognition, disease classification, and protein structure prediction.

Generative AI & foundation models represent the fastest-growing segment in the AI in Bioinformatics market, driven by their transformative potential in drug discovery, molecular design, and biological simulations. These technologies enable researchers to predict protein structures, accelerate clinical genomics, and design novel therapeutic molecules with unprecedented efficiency and accuracy.

By Application, genomics & sequence analysis dominates the AI in bioinformatics market, while clinical genomics & precision medicine is the fastest-growing segment

Genomics & sequence analysis was the leader in the AI in bioinformatics market because of the high adoption of AI for the purpose of DNA/RNA sequencing, variant identification, and gene mapping. The steady rise in the creation of genomic data, along with improvements in sequencing technology, contributed towards the adoption of AI-based solutions within this category.

Clinical genomics & precision medicine was the fastest growing category since the need for personalized medicine, target-specific therapy, and cancer genomics is steadily rising. The implementation of AI in clinical decision support system and diagnosis helped accelerate adoption.

By End User, pharmaceutical & biotechnology companies dominate the AI in bioinformatics market, while hospitals & diagnostic laboratories are the fastest-growing segment

The pharmaceutical and biotechnology companies contributed to the dominant share of AI in bioinformatics market in 2025 because there was widespread use of AI technology for drug discovery, biomarker discovery, clinical trials, and target validation. They constitute the main spenders on bioinformatics products which shorten the duration of research projects.

Hospitals and diagnostic laboratories witnessed the highest growth rate owing to increasing application of AI-powered diagnostics and genomics tests. There was also an increased use of precision medicine that helped detect diseases in their initial stages and develop personalized treatments.

Regional Analysis

North America AI in Bioinformatics Market Insights

North America accounted for the largest revenue share of 45.82% in the global AI in bioinformatics market in 2025 owing to significant investments made towards the development of biotechnology research, pharmaceutical advancements, and healthcare facilities enabled by the use of advanced AI tools in the U.S. and Canada. North America enjoys early adoption of advanced artificial intelligence solutions for genomics, drug discovery, and personalized medicine facilitated by its well-developed healthcare environment and significant presence of biotech and pharmaceutical firms.

Get Customized Report as per Your Business Requirement - Enquiry Now

This supremacy of North America is further enhanced by huge government investments and initiatives like that of NIH, coupled with increased funding for genomics and life sciences research, which have led to technological advancements in bioinformatics solutions with the aid of AI technology. Apart from this, North America also enjoys the presence of key players in the market and strong collaborations with various academic bodies and stakeholders.

Europe AI in Bioinformatics Market Insights

Europe is believed to be an important regional player in the market for AI in bioinformatics owing to its emphasis on innovative healthcare, extensive genomics research, and the adoption of artificial intelligence in life science applications. The nations of Germany, the UK, France, and Italy are among some of the leading nations driving regional growth because of their robust research capabilities, collaborations between academia and industry, and investments in precision medicine and computational biology. There has been an increase in the use of AI-powered bioinformatics solutions in genomics research, drug discovery, and clinical research within the region, as well.

Besides, regulatory policies and public investments through EU’s Horizon programs coupled with digital health initiatives from the European Commission have further enhanced market growth prospects in the region. The increasing incorporation of artificial intelligence within healthcare systems and the region’s emphasis on data-driven medical research make it a key contributor to global market growth.

Asia Pacific AI in Bioinformatics Market Insights

The Asia Pacific region is projected to experience the highest growth rate for the AI in bioinformatics market, with a CAGR of 18.63%. This is attributed to significant developments in healthcare infrastructure, growing applications of artificial intelligence technologies in life sciences, and investments in genomics and precision medicine in emerging economies. Emerging economies like China, India, Japan, and South Korea have been instrumental in fueling the expansion of the market in the region with their genomic research and growing biotech environment.

Additionally, favorable government initiatives in countries like China’s national genomics projects, India’s biotech industry promotion, and Japan’s efforts toward regenerative medicine and innovative healthcare practices via AI technologies are driving the AI in bioinformatics market. The collaborative efforts of global and regional biotech firms are making Asia Pacific the fastest-growing market for the AI in bioinformatics segment.

Middle East & Africa and Latin America AI in Bioinformatics Market Insights

Middle East & Africa and Latin America are witnessing a continuous rise in the AI in bioinformatics market owing to the rising investments made in the healthcare sector, growing capabilities in biotechnology, and increased usage of AI in the healthcare sector for research and diagnostics. In a similar fashion, in Latin America, growth in the AI in bioinformatics market is fueled by growth in healthcare facilities, investment in research and innovations in biotechnology, and the increasing usage of AI in diagnostic and bioinformatics applications.

Moreover, ongoing efforts towards the modernization of healthcare facilities in Latin America, along with increased interest in scientific research and innovations, have been further boosting the adoption of AI in bioinformatics.

Market Dynamics

Growth Drivers: Increasing focus on AI-driven drug discovery and precision medicine is accelerating market adoption

The increasing emphasis on AI-driven drug discovery, precision medicine, and large-scale genomic analysis has significantly accelerated the adoption of AI in bioinformatics solutions. The rising volume of biological data generated through next-generation sequencing, multi-omics studies, and clinical research has created a strong need for advanced AI-based platforms capable of managing, analyzing, and interpreting complex datasets. Growing demand for personalized healthcare and targeted therapies has further increased the use of AI in clinical genomics and diagnostic applications.

Restraints: High cost of AI infrastructure and data privacy concerns are limiting market expansion

The high cost associated with AI infrastructure, high-performance computing systems, and bioinformatics platforms is acting as a major restraint for market growth, particularly among small and mid-sized research organizations. The requirement for advanced computational resources and specialized software tools increases overall operational expenses, limiting widespread adoption. In addition, concerns related to data privacy, security, and regulatory compliance in handling sensitive genomic and clinical data are restricting the scalability of AI-based bioinformatics solutions.

Opportunities: Rising adoption of generative AI and multi-omics integration is creating new growth avenues

The increasing adoption of generative AI, foundation models, and advanced machine learning techniques is creating significant growth opportunities in the AI in bioinformatics market. These technologies are enabling faster drug discovery, novel molecule design, and improved protein structure prediction, thereby transforming computational biology workflows. Growing integration of AI with multi-omics data (genomics, proteomics, metabolomics, and transcriptomics) is opening new possibilities for deeper biological insights and disease understanding.

Recent Developments

• 2026: Thermo Fisher Scientific expanded its AI-driven bioinformatics and life sciences analytics portfolio by strengthening its genomic sequencing platforms and cloud-based data interpretation capabilities, enhancing support for large-scale multi-omics research and precision medicine applications across pharmaceutical and clinical research markets.

• 2025: Eurofins Scientific advanced its bioinformatics and laboratory analytics capabilities through integration of AI-powered data analysis systems across genomic testing and clinical diagnostics workflows, improving speed and accuracy of sequencing interpretation and supporting growing demand for personalized healthcare solutions.

• 2025: Insilico Medicine accelerated its AI-driven drug discovery pipeline by expanding its generative AI platforms for target identification and molecule design, strengthening its focus on end-to-end computational biology solutions aimed at reducing drug development timelines and improving success rates in early-stage research.

• 2026: SOPHiA GENETICS enhanced its cloud-based AI healthcare analytics platform by expanding partnerships with hospitals and research institutions, enabling improved real-time genomic data interpretation and scaling adoption of precision medicine solutions across oncology and rare disease diagnostics.

AI in Bioinformatics Market Key Players are:

• Thermo Fisher Scientific

• Eurofins Scientific

• Insilico Medicine

• SOPHiA Genetics

• QIAGEN

• Genedata

• Paige AI

• SomaLogic

• Source BioScience

• Fios Genomics

• Recursion Pharmaceuticals

• Isomorphic Labs

• XtalPi

• Google DeepMind

• IBM Research

• NVIDIA

• Microsoft

• Oracle

• Amazon AWS

• Palantir

AI in Bioinformatics Market Report Scope: